Clinical Trial: Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07174453) titled 'Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies' on Sept. 12.

Brief Summary: Phase 3/4 open label, randomized two cohort study (2 arms in each cohort).

It is hypothesized that for people with a histologically or cytologically confirmed diagnosis of malignancy, the higher dose immunotherapy (every 6 weeks Pembrolizumab 400mg dose and every 4 weeks Nivolumab 480mg dose) has more immune-related adverse events irAEs compared to lower dose (every 3 weeks Pembrolizumab 200mg dose and every 2 weeks Nivolumab 240mg dose).

Study Start Date: Oct. 01

Study Type: INTERVENTIONAL ...